Zimbabwe has turned down a significant American healthcare agreement valued at $367m (£272m) spanning five years due to Washington's request for confidential biological samples.
This rejection was revealed following a internal memorandum dated December was disclosed, revealing that President Emmerson Mnangagwa believed the arrangement was "unbalanced".
A government spokesman later stated that the US was demanding access to health data for scientific study and commercial gain but was not willing to guarantee the resulting advantages from any future medical innovations.
"We must now begin the challenging and unfortunate process of winding down our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had provided over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has urged continued dialogue to reach a agreement agreeable to both sides so the country's vital HIV treatment initiative can continue.
Wider Context
This rejection follows a similar case in neighbouring Kenya, where a court blocked a similar deal with the US after legal challenges were filed about the security of citizens' health data.
After returning to the presidency last year, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
USAID had managed assistance for the US government, but Trump stated its expenditure was "inefficient" and his administration was seeking government-to-government agreements to enhance openness and accountability.
Based on statements, Sixteen nations in Africa have so far signed similar agreements, constituting over $18.3bn of fresh investment.
Specifics of the Rejected Agreement
This assistance for Zimbabwe was intended to gone towards "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this partnership would have delivered extraordinary advantages for Zimbabwean communities, particularly the 1.2 million currently on antiretroviral therapy through American-funded programmes," Tremont added.
However, official spokesman Nick Mangwana said the proposed deal was "unequal".
"Zimbabwe was being asked to share its biological resources and data for a long time, without any equivalent guarantee of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that provided information," Mangwana explained.
"Effectively, our country would provide the raw materials for scientific discovery without any certainty that the resulting innovations would be accessible to our people if a new pandemic emerge."
Sovereignty and Global Health
Mangwana further noted that the American exit from the World Health Organization (WHO) and its pursuit of bilateral deals were disrupting systems previously established through the international organization.
Mangwana cited its Pandemic Benefit-Sharing scheme created to deal with future global health emergencies.
"This framework is intended to guarantee that when a country contributes its data, the resulting advantages – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the funds to develop them."
These objections regarding the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We welcome further discussions with our American counterparts on how future co-operation might be designed in a manner that respects the sovereignty and dignity of each country."
Medical Community Response
Medical experts stated it understood the official position, but suggested that talks need to persist since much of the nation's Aids initiatives were funded by foreign aid.
"If specific concerns exist, such as those relating to data governance or implementation frameworks, these can frequently be resolved via detailed discussion and mutually agreed protections," it said.
The halted deal underscores the complex tensions between accepting crucial foreign assistance and safeguarding national sovereignty in an ever more data-driven world.